COX-2 and Non-Selective NSAID Use in Those at Increased Risk of NSAID-Related Adverse Events

被引：0

作者：

Ilomaki, Jenni ^{[1
]}

Gadzhanova, Svetla ^{[1
]}

Roughead, Elizabeth E. ^{[1
]}

机构：

[1] Univ S Australia, Sch Pharm & Med Sci, Sansom Inst, Qual Use Med & Phrmacy Res Ctr, Adelaide, SA 5001, Australia

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2012年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

145

引用

页码：70 / 70

页数：1

共 50 条

[31] Esomeprazole relieves NSAID-associated upper GI symptoms in patients taking either continuous cox-2 selective nsaids or non-selective nsaids
Kean, W
JOURNAL OF RHEUMATOLOGY, 2005, 32 (07) : 1389 - 1389
[32] NSAID + PPI: less risk of dyspepsia than COX-2's
Reactions Weekly, 2005, 1054 (1) : 4 - 4
[33] COX-2 selective and non-selective NSAIDs and the risk of acute myocardial infarction
Andersohn, Frank
Suissa, Samy
Garbe, Edeltraut
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S59 - S59
[34] Major GI events among cox-2 inhibitor, NSAID, and aspirin users
Mullins, CD
Tran, BV
Shaya, FT
Naradzay, JF
Howard, KB
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S271 - S272
[35] The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy
Yood, Marianne Ulcickas
Watkins, Emmeline
Wells, Karen
Kucera, Gena
Johnson, Christine Cole
Lydick, Eva
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 (12) : 852 - 860
[36] REDUCED RISK OF NSAID INDUCED ADVERSE EVENTS WITH CONCOMITANT USE OF MISOPROSTOL
Munger, Mark A.
Nelson, Scott D.
Teng, Chia-Chen
Bress, Adam
Sauer, Brian C.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 1759 - 1759
[37] Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes
Vogel, Ulla
Christensen, Jane
Wallin, Hakan
Friis, Soren
Nexo, Bjorn A.
Tjonneland, Anne
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2007, 617 (1-2) : 138 - 146
[38] Population level associations between COX-2 Inhibition by NSAID use and prostate cancer risk
Veitonmaki, T. P. C.
Tammela, T. L. J.
Auvinen, A.
Murtola, T. J.
EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E266 - E266
[39] Uptake of COX-2 selective inhibitors and influence on NSAID prescribing in Northern Ireland
Girvin, B
Rafferty, T
Stevenson, MR
Johnston, GD
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2004, 13 (03) : 153 - 157
[40] PPIs or COX-2 inhibitors reduce risk of gastrointestinal ADRs from NSAID + anticoagulant use
Reactions Weekly, 2022, 1895 (1) : 10 - 10

← 1 2 3 4 5 →